Romania - Romanian - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

Romania - Romanian - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

Romania - Romanian - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

Romania - Romanian - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

Romania - Romanian - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

Romania - Romanian - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

Moldova - Romanian - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

therdose pharma pvt. ltd. - irinotecanum - concentrat pentru solutie perfuzabila - 100 mg/5 ml

European Union - Romanian - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccinuri - profilaxia gripei cauzate de virusul a (h1n1) v 2009. celvapan ar trebui să fie utilizate în conformitate cu recomandările oficiale.

European Union - Romanian - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpură, trombocitopenică, idiopatică - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 și 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 și 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

European Union - Romanian - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemie, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.